This is important because confirmation of “oncogene addiction” (reviewed in14,15) to mutant HRAS or interrelated components of the FGFR3 or PI3K/AKT/mTOR pathways would allow development of targeted approaches to treat noninvasive bladder cancer. The gene discussed is FGFR3; the disease is urinary bladder cancer.